CLS Therapeutics Inc., an oncology focused gene therapy company, today announced that their project was selected as one of the 15 finalists to compete for the Boehringer Ingelheim Innovation Prize during the evening of August 15 at NYU Langone Health.
Dr. Tetz’s presentation would provided an overview of CLS-014, an engineered gene therapy platform addressing unmet need in pancreatic cancer with multiple follow-up extension opportunities. CLS-014 is an AAV vector that employs cblood circulating cell-free tumor DNA and neutrophil extracellular traps as novel therapeutic targets for the treatment of solid tumors.
Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced the signing of a patent assignment from CLS Therapeutics, Inc. (“CLS”) to Xenetic related to Xenetic’s previously announced collaboration with VolitionRx Limited (NYSE AMERICAN:VNRX) (“Volition”), a multi-national epigenetics company, and CLS, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets. In consideration of the patent assignment, Xenetic will also issue 850,000 shares of common stock to CLS.
NEW YORK, NY / July, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data at the annual meeting of the American Society of Clinical Oncology (ASCO).
NEW YORK, March 28, 2019 – CLS Therapeutics, Inc., today announced a poster presentation “First-In-Class -AAV-Based Gene Therapy For Pancreatic Cancer Based On The Destruction Of Cell-Free DNA with Vector-delivered DNase I” at the New York Academy of Sciences symposium “Targeting Tumor Heterogeneity” being held on May 8, 2019, in New York City. The presentation includes the first animal data for the activity of AAV-based vector (in silico designed ) encoding DNase I of the treatment of pancreatic cancer animal model.